Assessment of Knowledge, Attitude, and Practice Patterns in Pulmonary Arterial Hypertension among Cardiologists and Pulmonologists: Evidence from Turkey

• Published in: Medicina (Kaunas, Lithuania) Lithuania), 2023-10, Vol.59 (10), p.1869
• Main Authors: Günaydın, Fatma Esra, Belen, Erdal, Altın, Sedat, Demir, Ahmet Uğur, Güven, Gülden, Durmuş, Gündüz
• Format: Article
• Language: English
• Subjects: Adult; Cardiologists; Cardiology; Chronic diseases; Clinical medicine; diagnosis; disease management; Dyspnea; education; Endothelin; guideline adherence; Health Knowledge, Attitudes, Practice; Hospitals; Humans; Hypertension, Pulmonary - etiology; Lung transplants; Medical diagnosis; Medical societies; Medicine; Mortality; Patient compliance; Patients; Phosphodiesterase 5 Inhibitors - therapeutic use; Physicians; Practice; pulmonary arterial hypertension; Pulmonary Arterial Hypertension - complications; Pulmonary Arterial Hypertension - drug therapy; Pulmonary arteries; Pulmonary hypertension; Pulmonologists; questionnaire; Questionnaires; Society; Surveys; Turkey
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina59101869

: Pulmonary arterial hypertension (PAH) is a rare chronic disease of the small pulmonary arteries that causes right heart failure and death. Accurate management of PAH is necessary to decrease morbidity and mortality. Understanding current practices and perspectives on PAH is important. For this purpose, we intended to determine physicians' knowledge, attitudes, and practice patterns in adult pulmonary arterial hypertension (PAH) in Turkey. : Between January and February 2022, an online questionnaire was sent via e-mail to all cardiologists and pulmonologists who were members of the Turkish Society of Cardiology (TSC) and the Turkish Thoracic Society (TTS). : A total of 200 physicians (122 pulmonologists and 78 cardiologists) responded to the questionnaire. Cardiologists were more frequently involved in the primary diagnosis and treatment of PAH than pulmonologists (37.2% vs. 23.8%, = 0.042). More than half of the physicians had access to right heart catheterization. In mild/moderate PAH patients with a negative vasoreactivity test, the monotherapy option was most preferred (82.8%) and endothelin receptor antagonists (ERAs) were the most preferred group in these patients (73%). ERAs plus phosphodiesterase-5 inhibitors (PDE-5 INH) were the most preferred (69%) combination therapy, and prostacyclin analogues plus PDE-5 INH was preferred by only pulmonologists. : Overall, clinical management of patients with PAH complied with guideline recommendations. Effective clinical management of PAH in specialized centers that having right heart catheterization achieve better outcomes.